

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/685,823
DATE: 10/20/2000
TIME: 10:53:33Input Set : A:\P1834US.txt
Output Set: N:\CRF3\10202000\I685823.raw

3 <110> APPLICANT: Filvaroff, Ellen H.
5 <120> TITLE OF INVENTION: Use of IL-17 and LIF Antagonists for the Treatment of
6 Cartilaginous Disorders
8 <130> FILE REFERENCE: P1834US
W--> 10 <140> CURRENT APPLICATION NUMBER: US/09/685,823
10 <141> CURRENT FILING DATE: 2000-10-09
12 <150> PRIOR APPLICATION NUMBER: US 09/311,832
13 <151> PRIOR FILING DATE: 1999-05-14
15 <150> PRIOR APPLICATION NUMBER: US 09/380,142
16 <151> PRIOR FILING DATE: 1999-08-25
18 <150> PRIOR APPLICATION NUMBER: US 60/192,103
19 <151> PRIOR FILING DATE: 2000-03-24
21 <160> NUMBER OF SEQ ID NOS: 3
23 <210> SEQ ID NO: 1
24 <211> LENGTH: 9
25 <212> TYPE: PRT
26 <213> ORGANISM: Artificial sequence
28 <220> FEATURE:
29 <223> OTHER INFORMATION: Ovalbumin-derived antigenic peptide.
31 <400> SEQUENCE: 1
32 Ala Arg Gly Ser Val Ile Gly Gly Cys
33 1 5
35 <210> SEQ ID NO: 2
36 <211> LENGTH: 10
37 <212> TYPE: PRT
38 <213> ORGANISM: Artificial sequence
40 <220> FEATURE:
41 <223> OTHER INFORMATION: Ovalbumin-derived antigenic peptide.
43 <400> SEQUENCE: 2
44 Phe Phe Gly Val Gly Ala Lys Lys Gly Cys
45 1 5 10
47 <210> SEQ ID NO: 3
48 <211> LENGTH: 5
49 <212> TYPE: PRT
50 <213> ORGANISM: Artificial sequence
52 <220> FEATURE:
53 <223> OTHER INFORMATION: N-terminal aggrecan cleavage fragment.
55 <400> SEQUENCE: 3
56 Ala Arg Gly Ser Val
57 1 5

ENTERED

RECEIVED
JAN 24 2001
TECH CENTER 1600/2900

VERIFICATION SUMMARY
PATENT APPLICATION: US/09/685,823

DATE: 10/20/2000
TIME: 10:53:34

Input Set : A:\P1834US.txt
Output Set: N:\CRF3\10202000\I685823.raw

L:10 M:282 W: Numeric Field Identifier Missing, <140> CURRENT APPLICATION NUMBER: is Added.

RECEIVED

JAN 24 2001

TECH CENTER 10202000